Spinal Nerve Ligation (SNL) Model Development Service
Are you currently facing challenges in creating consistent and reproducible animal models for chronic neuropathic pain, or struggling with long drug development cycles? Our spinal nerve ligation (SNL) models development service helps you accelerate drug discovery by providing a validated, high-quality preclinical platform. Through a refined surgical protocol and rigorous quality control measures, we ensure your studies begin with a reliable foundation, allowing you to focus on therapeutic development.
Neuropathic pain is a complex and debilitating condition that affects millions, and effective treatments remain a major unmet medical need. The SNL model is a cornerstone of preclinical pain research, providing a critical platform to study the mechanisms of chronic neuropathic pain. By selectively ligating the L5 and L6 spinal nerves in rodents, the model reliably mimics the persistent pain symptoms experienced by patients with nerve root compression. It is an invaluable tool for screening and validating novel analgesic compounds.
How Our SNL Models Development Service Can Assist Your Project
Our SNL models development service provides a comprehensive solution for studying chronic neuropathic pain, ensuring your research is built on a foundation of scientific rigor and consistency. We deliver a validated animal model that reliably produces the key behavioral symptoms of neuropathic pain, along with the robust data needed to confidently evaluate your therapeutic candidates. This service eliminates the technical and operational complexities of in-house model development, giving you a clear path forward in your drug discovery program.
Discover How We Can Help - Request a Consultation.
Workflow
Our process is designed for clarity and efficiency, ensuring a seamless journey from initial concept to final data delivery.
-
Required Starting Materials: To initiate a project, clients typically provide the following:
- Project Scope and Objectives: A detailed description of your research goals and the specific questions you aim to answer.
- Compound Information: Details regarding the therapeutic agent to be tested, including dose ranges, administration routes, and schedule.
- IACUC Protocol Approval: Your institution's approved protocol covering the use of the SNL model and any specific study procedures.
-
Final Deliverables: Upon completion, you will receive:
- A detailed, publication-ready study report.
- Raw and analyzed behavioral data files for your own records.
- Relevant IACUC documentation and study records.
- Estimated Timeframe: The typical timeframe for a standard SNL model development and a 14-day efficacy study ranges from 4 to 6 weeks, depending on the complexity of the protocol and the number of animals required.
Why Choose Us?
Choosing the right partner for your preclinical research is crucial for the success of your program. Our SNL models development service stands out due to our deep scientific expertise, commitment to model consistency, and comprehensive suite of assessment capabilities. We have refined the SNL model to overcome the challenges of surgical variability and non-specific trauma, resulting in highly reliable data that you can trust. Our approach focuses on delivering not just a service, but a true partnership dedicated to advancing your research.
Experience the Advantage - Get a Quote Today.
Customer Reviews:
[Improved Reproducibility] Using CBL's SNL models development service in our research has significantly improved the reproducibility of our neuropathic pain studies. The in-house models we had previously developed showed high variability, but the low-trauma approach used by CBL provided us with a far more consistent platform, allowing us to generate reliable dose-response curves. – [3 months ago], K*****e S.
[Tangible Data] Our experience with CBL's SNL service was excellent. We were able to leverage their expertise to not only assess behavioral endpoints but also to include histological and biomarker analysis. The ability to combine von Frey data with protein expression levels in the DRG gave us a much deeper understanding of our compound's mechanism of action. – [4 weeks ago], P*****l N.
[Expert Consultation] We initially considered developing the SNL model ourselves, but after a consultation with the team at CBL, we realized the value of their specialized service. Their deep knowledge of the model's nuances and their rigorous quality control measures saved us a tremendous amount of time and resources. The data we received was impeccable and allowed us to move forward with our research with confidence. – [8 months ago], J*****n M.
Spinal Nerve Ligation (SNL) Models
The SNL model, originally established in the early 1990s, has become a gold standard for investigating the pathophysiology of chronic neuropathic pain. This model is based on the principle of inducing a peripheral nerve injury that results in long-lasting, clinically relevant pain behaviors.
The core mechanism involves the tight ligation of the L5 and L6 spinal nerves, leaving the L4 nerve intact. This selective injury induces axonal degeneration in the affected nerves while allowing researchers to study the critical changes that occur in both the injured and adjacent, uninjured sensory neurons. The resulting pain behaviors, most notably mechanical and cold allodynia, are persistent and robust, making the model ideal for evaluating the efficacy and duration of action of potential therapeutic agents.
The SNL model is particularly valuable for its clinical relevance, as the pain behaviors it produces are highly analogous to human conditions like lumbar disc herniation. The model allows for the detailed study of molecular changes, including altered gene expression and protein levels in the dorsal root ganglia (DRG) and spinal cord, providing a powerful platform for mechanistic research.
What We Can Offer
- High-Quality, Reproducible Models: We provide a reliable and consistent SNL model for preclinical studies, ensuring minimal variability in behavioral outcomes.
- Refined Surgical Technique: Our experienced surgeons employ a low-trauma oblique lateral approach to minimize non-specific tissue damage and reduce postoperative complications, enhancing the validity of your study.
- Customized Study Design: We offer flexible and tailored study protocols, allowing you to select specific animal strains, surgical approaches (L5 only or L5/L6 ligation), and study durations to meet your unique research needs.
- Comprehensive Assessment Capabilities: Beyond standard behavioral testing, we offer a range of advanced endpoints, including histological analysis (IHC), biomarker quantification (protein and mRNA), and electrophysiological recordings.
- Full Regulatory Compliance: All our procedures are conducted under the strict governance of our Institutional Animal Care and Use Committee (IACUC), and we work with you to ensure your project meets all regulatory requirements.
- End-to-End Scientific Partnership: We function as a true partner, providing expert consultation from initial study design through final data analysis, ensuring you have the support needed for a successful project.
Related Services
Our expertise in neuropathic pain research extends beyond the SNL model. To further support your drug discovery efforts, we offer a range of complementary services that can be integrated with your SNL study or utilized as standalone projects.
- Acute Pain Models
- Inflammatory Pain Models
- Biomarker Development & Validation
- Neuroinflammation Studies
Ready to take the next step in your neuropathic pain research? Our team of experts is ready to assist you.
Contact Our Team for More Information and to Discuss Your Project.
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Rat Muller Cell (Cat#: NCL2110P040)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)